Articles related to CLINICAL TRIALS

First-line pembrolizumab and pembrolizumab-chemotherapy continued to outperform cetuximab-chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma after a 4-year follow-up. Following pembrolizumab-based therapy, patients responded well to subsequent treatment.

This MashupMD link provides a video critique on YouTube of an NEJM paper on colonoscopy screening.

Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial The rates of grades 2, 3, 4, and 5 toxic effects were 14.2%, 4.2%, 0%, and 0.3%, respectively, in this population-based phase 2 nonrandomized clinical trial of 381 patients with oligometastatic or oligoprogressive disease that was designed to capture toxic effects prospectively as the primary end point.

Incidences of dizziness, dissociation, increased blood pressure, nausea, vertigo, and sedation were highest in week 1 of treatment and the majority are mild or moderate in severity.

In the confirmatory trial, Clarity AD, of 1,795 patients with early AD, findings showed a reduction of dementia scoring of 27% vs. placebo. These findings were seen as early as 6 months.

In the 5-year, multi-center, randomized, controlled GRADE trial (Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study), insulin glargine and liraglutide were about 13% more effective than glimepiride in keeping HbA1c lower than 7.0%, and 30% more effective than sitagliptin.